Device Trial Radar · NCT04809285
Use of the Guardian™ Connect System With Smart Connected Devices
Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Apr 6, 2021
Primary completion
Sep 29, 2023
Study completion Sep 29, 2023
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.
Conditions
- Type 1 Diabetes Mellitus
Interventions
Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management appDevice
Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Time in HypoglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2
- Percentage of Time in EuglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2
- Percentage of Time in HyperglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Diabetes and Endocrinology Center
Little Rock, Arkansas
Loma Linda University Medical Center
Loma Linda, California
Mary and Dick Allen Diabetes Center
Newport Beach, California
11 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.